Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Ulcerative Colitis
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
- Trial name
- NCT05181137
- Testing
- SHR0302
- Where
- 113 sites in United States, China and 3 more
- Volunteers
- 368 people
- Sponsor
- Reistone Biopharma Company Limited
Healthy
Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects
The goal of this clinical trial is to investigate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of BCD-261 after single subcutaneous injection at ascending doses and proposed therapeutic doses…
- Trial name
- NCT06715540
- Testing
- BCD-261, dose 1, BCD-261, dose 2, BCD-261, dose 3
- Where
- Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Biocad
Colitis, Ulcerative
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical…
- Trial name
- NCT01294410
- Testing
- Anti-IP-10 Antibody
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 305 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis
Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
The objective of the proposed study is to determine whether BL-7040 demonstrates clinical efficacy in patients with inflammatory bowel disease (IBD).
- Trial name
- NCT01506362
- Testing
- BL-7040
- Where
- 5 sites in Israel
- Volunteers
- 22 people
- Sponsor
- BioLineRx, Ltd.
Colitis, Ulcerative
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis
This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.
- Trial name
- NCT07747480
- Testing
- Aletekitug
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Colitis, Ulcerative
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.
- Trial name
- NCT03412682
- Testing
- Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg)
- Where
- 72 sites in Japan
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)
This is a prospective, randomized, double-blind, sham treatment controlled multicenter study.
- Trial name
- NCT00947674
- Testing
- Cellsorba EX
- Where
- 10 sites in Czechia, Germany and 4 more
- Volunteers
- 52 people
- Sponsor
- Asahi Kasei Medical Co., Ltd.
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Colitis, Ulcerative
Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476
Evaluate the percentage of subjects in remission at the end of an 8-week treatment period for three dose groups (SPD476 1.2 g/day, 2.4 g/day or 4.8 g/day, administered once daily).
- Trial name
- NCT00545389
- Testing
- SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- Shire
Colitis, Ulcerative
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- VEGA (NCT03662542)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1
- Where
- 82 sites in United States, Argentina and 7 more
- Volunteers
- 214 people
- Sponsor
- Janssen Research & Development, LLC
Ulcerative Colitis
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
To evaluate the long-term safety and tolerability of encapsulated mesalamine Granules (eMG) (formerly referred to as Mesalamine Pellets [MP]) in participants with ulcerative colitis currently in remission.
- Trial name
- NCT00326209
- Testing
- Encapsulated Mesalamine Granules (eMG)
- Where
- 61 sites in United States
- Volunteers
- 393 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
- Trial name
- NCT00307827
- Testing
- Visilizumab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Abbott
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- LUCENT-ACT (NCT04469062)
- Testing
- Mirikizumab IV, Mirikizumab SC, Vedolizumab IV
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.
- Trial name
- NCT05404074
- Testing
- Cobitolimod 500mg
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- InDex Pharmaceuticals
Ulcerative Colitis
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single…
- Trial name
- NCT07869225
- Testing
- EQ504
- Where
- Australia
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Equillium
Ulcerative Colitis
Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
This is a Phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to severely active ulcerative colitis
- Trial name
- NCT04096573
- Testing
- LC51-0255
- Sponsor
- LG Chem
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Ulcerative Colitis
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
- Trial name
- NCT02447302
- Testing
- Etrasimod
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 156 people
- Sponsor
- Arena Pharmaceuticals
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Inflammatory Bowel Diseases, Ulcerative Colitis
Enhancing Ultrasound & Photoacoustic for Recognition of Intestinal Abnormalities
The clinical investigation aims to generate clinical data to support the use of Multispectral Optoacoustic Tomography (MSOT) in clinical practice, its inclusion in diagnostic guidelines and to support its reimbursement…
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- EUPHORIA (NCT04456400)
- Testing
- Multispectral Optoacoustic Tomography (MSOT)
- Where
- 6 sites in Germany, Italy
- Volunteers
- 200 people
- Sponsor
- iThera Medical GmbH